The $583,000 four-year research award will aid research using monoclonal antibodies to lower the chances of non-Hodgkin lymphoma relapse, complications
May 14, 2012
The Fred Hutchinson Cancer Research Center's Dr. Andrew Rezvani has received a four-year, $583,000 mentored research scholar grant from the American Cancer Society. The award supports his work in improving outcomes for patients who receive blood and bone marrow transplants to treat non-Hodgkin lymphoma.
According to data compiled by the National Cancer Data Base, survival rates among patients treated for eight types of cancer top other programs accredited by Commission on Cancer
Feb. 21, 2012
| By Dean Forbes
Five-year survival rates among patients treated by Seattle Cancer Care Alliance for eight types of cancer are higher than for patients treated at the other cancer programs accredited by the Commission on Cancer of the American College of Surgeons. The National Cancer Data Base (NCDB), which is operated jointly by the commission with the American Cancer Society, compiled the survival rate data.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.